Flow cytometric analysis of Rat CD161 expression on SD Rat splenocytes. SD Rat splenocytes were stained with Alexa Fluor® 488 Mouse Anti-Rat CD3 Antibody and either Alexa Fluor® 647 Mouse IgG1, κ Isotype Control (Left panel) or SDT Alexa Fluor® 647 Mouse Anti-Rat CD161 Antibody (Right panel) at 5μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Product Details
Product Details
Product Specification
Host | Mouse |
Antigen | CD161 |
Synonyms | Killer cell lectin-like receptor subfamily B member 1A; NKR-P1A; Antigen 3.2.3; CD161 antigen-like family member A; Natural killer cell surface protein P1-3.2.3 (NKR-P1 3.2.3); CD161a; Nkrp1a; Klrb1a |
Location | Membrane |
Accession | P27471 |
Clone Number | S-R628 |
Antibody Type | Mouse mAb |
Isotype | IgG1,k |
Application | FCM |
Reactivity | Rt |
Positive Sample | SD Rat splenocytes |
Purification | Protein G |
Concentration | 0.02mg/ml |
Conjugation | Alexa Fluor® 647 |
Physical Appearance | Liquid |
Storage Buffer | PBS, 25% Glycerol, 1% BSA, 0.3% Proclin 300 |
Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied. |
Dilution
application | dilution | species |
FCM | 5μl per million cells in 100μl volume | Rt |
Background
CD161, also known as KLRB1 or NKRP1A, is a C-type lectin-like receptor primarily expressed on the surface of natural killer (NK) cells and a subset of T cells, including mucosal-associated invariant T (MAIT) cells and some CD8+ T cells. It is particularly enriched in immune cells located in mucosal sites such as the gut and liver. CD161 binds to its ligand, lectin-like transcript 1 (LLT1, also known as CLEC2D), and this interaction can have both inhibitory and costimulatory effects on immune cells. In the context of cancer immunotherapy, CD161 has been identified as a potential inhibitory receptor in glioma-infiltrating T cells. Its activation by CLEC2D on tumor or immunosuppressive cells can dampen T cell responses against cancer cells. Recent studies suggest that blocking the CD161-CLEC2D interaction may enhance T cell-mediated antitumor activity, making CD161 a promising target for cancer immunotherapy.
Picture
Picture
FC
